Frank McCormick

Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996.

At Onyx Pharmaceuticals, he initiated and directed drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharangeal cancer. Furthermore, Dr. McCormick�s group led to the identification of a CDK4 kinase inhibitor that is currently in Phase II clinical trials. In addition to his position as Director of the UCSF HDFCCC, Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of 285 scientific publications and holds 20 issued patents. He is on the advisory boards of Memorial Sloane Kettering, Dana Farber Cancer Center, the Canary Foundation, the University of Wisconsin Comprehensive Cancer Center, and the University of Texas, Southwestern Advisory Board.

Dr. McCormick is also the 2012-2013 President of the American Association for Cancer Research (AACR) multiple disease areas.